Bezafibrate lowers very long-chain fatty acids in X-linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation
- First Online:
- Cite this article as:
- Engelen, M., Schackmann, M.J.A., Ofman, R. et al. J Inherit Metab Dis (2012) 35: 1137. doi:10.1007/s10545-012-9471-4
X-linked adrenoleukodystrophy (X-ALD) is caused by mutations in the ABCD1 gene encoding ALDP, an ATP-binding-cassette (ABC) transporter located in the peroxisomal membrane. ALDP deficiency results in impaired peroxisomal β-oxidation and the subsequent accumulation of very long-chain fatty acids (VLCFA; > C22:0) in plasma and tissues. VLCFA are primarily derived from endogenous synthesis by ELOVL1. Therefore inhibiting this enzyme might constitute a feasible therapeutic approach. In this paper we demonstrate that bezafibrate, a PPAR pan agonist used for the treatment of patients with hyperlipidaemia reduces VLCFA levels in X-ALD fibroblasts. Surprisingly, the VLCFA-lowering effect was independent of PPAR activation and not caused by the increase in either mitochondrial or peroxisomal fatty acid β-oxidation capacity. In fact, our results show that bezafibrate reduces VLCFA synthesis by decreasing the synthesis of C26:0 through a direct inhibition of fatty acid elongation activity. Taken together, our data indicate bezafibrate as a potential pharmacotherapeutic treatment for X-ALD. A clinical trial is currently ongoing to evaluate the effect in patients with X-ALD.
X-linked adrenoleukodystrophy (X-ALD: OMIM 300100) is an inherited metabolic disorder characterized by impaired peroxisomal β-oxidation of very long-chain fatty acids (VLCFA; ≥C22) and accumulation of VLCFA (mainly ≥C26:0) in plasma and tissues of patients (Moser et al 2001). It is caused by mutations in the ABCD1 gene (http://www.x-ald.nl), encoding a peroxisomal transmembrane protein named ALD protein (ALDP: OMIM 300371) (Mosser et al 1993). Clinically, X-ALD is characterized by a striking and unpredictable variation in phenotypic expression, ranging from the rapidly progressive childhood cerebral form (CCALD) to the more slowly progressive adult form adrenomyeloneuropathy (AMN) and variants without neurological involvement (“Addison-only” phenotype) (Moser et al 2001).
Experimental pharmacotherapy in X-ALD was aimed at normalizing VLCFA β-oxidation and VLCFA levels. Over the years several compounds have been investigated, such as Lorenzo’s oil (Aubourg et al 1993; van Geel et al 1999), 4-phenylbutyrate (Kemp et al 1998), and lovastatin (Engelen et al 2010; Singh et al 1998). These treatments were shown to be either unpractical or ineffective in clinical trials and therefore other drugs are needed.
Fenofibrate (a PPAR-α agonist) was shown to induce expression of ALDR (Abcd2) in the liver of Abcd1 -/- mice (Netik et al 1999). ALDRP is a functional homolog of ALDP (Kemp et al 1998). However, fenofibrate has no effect on Abcd2 expression in the brain of Abcd1 -/- mice, possibly because it is a substrate for the Mdr1 transporter at the blood brain barrier and therefore does not penetrate into the brain very effectively (Berger et al 1999). For this reason, we investigated the effect of several other drugs known to activate PPAR on VLCFA metabolism in cultured skin fibroblasts from patients with X-ALD. The results described in this paper show that bezafibrate (BF), but not fenofibrate, clofibrate or other PPAR agonists, could reduce VLCFA in cultured fibroblasts from patients with X-ALD.
The VLCFA which accumulate in X-ALD, are partly absorbed from the diet (Kishimoto et al 1980), but mostly result from endogenous synthesis through elongation of long-chain fatty acids (Tsuji et al 1981). Recently, we identified ELOVL1 as the key enzyme responsible for the synthesis of VLCFA and demonstrated that knock-down of ELOVL1 resulted in lower VLCFA synthesis and reduced levels of VLCFA in cultured X-ALD fibroblasts (Ofman et al 2010). Hence, inhibiting fatty acid elongation (for example by inhibition of ELOVL1) by pharmacological means could be a potential treatment for X-ALD. Here, we show that BF lowers VLCFA in X-ALD fibroblasts by direct inhibition of fatty acid elongation.
Materials and methods
Deuterium-labeled palmitate-16,16,16-D3 acid (D3C16:0) was purchased from CDN isotopes (Pointe-Claire, Canada). A 12.5 mM stock solution in dimethyl sulfoxide (DMSO) was prepared. BF, fenofibrate and clofibrate, WY14643, GW501516, and rosiglitazone were purchased from Sigma-Aldrich (St. Louis, MO, USA). Stock solutions in DMSO were made of 400 mM (BF and clofibrate), 50 mM (fenofibrate), 10 mM (WY14643 and rosiglitazone), 500 μM (GW501516). MK-886 was purchased from Cayman Chemical (Ann Arbor, MI, USA) and a stock solution of 50 mM in DMSO was used. Prior to usage the stock solutions were vortex mixed and diluted in HAMF10 tissue culture medium to the final concentration. All chemicals used were of analytical grade.
Cell lines and cell culture
Primary human skin fibroblasts were obtained from X-ALD patients through the Neurology Outpatient Clinic of the Academic Medical Center. From each patient written informed consent was obtained. X-ALD diagnosis was confirmed by VLCFA and ABCD1 mutation analysis. Control fibroblasts were from male anonymous volunteers. Cells from patients with a peroxisomal biogenesis disorder were obtained from the laboratory cell bank. Cells were grown in HAMF10 supplemented with 10% fetal calf serum, 2.5 mM HEPES, 100 U/ml penicillin, 100 U/ml streptomycin and 2 mM glutamine. Cells were used between passage numbers 6 and 20. Culture media were refreshed every 5 days.
Fatty acid synthesis
Synthesis of D3-VLCFA in intact cells was measured using D3-C16:0. Assays were performed in triplicate. Cells were seeded at 40% confluency in T75 flasks. The next day, medium was replaced by fresh medium supplemented with D3-C16:0 (dissolved in DMSO) at a final concentration of 50 μM. After 72 hr, cells were harvested and VLCFA analyzed as described (Valianpour et al 2003).
Measurement of fatty acid β-oxidation
Mitochondrial β-oxidation activity of intact fibroblasts was measured by quantifying the production of 3H2O from [9,10-3H(N)] oleic acid as described previously (Moon and Rhead 1987). Peroxisomal β-oxidation activity of intact fibroblasts was measured using [1-14 C]-26:0 as described previously (Wanders et al 1995). All measurements were performed in triplicate for each cell line.
Immunofluorescence and counting of peroxisomes
Fibroblasts where grown on glass microscopy slides in 6-well plates with or without 400 μM BF. Cells were fixed with paraformaldehyde and permeabilized with Triton X-100. Peroxisomes were visualized by catalase immunofluorescence microscopy as described previously (Kemp et al 1996). To count peroxisomes, we made images of immunofluorescence-stained cells after focusing on the cell nucleus, and determined the peroxisome number per cell with the aid of a colony counter. For each cell line and condition, 10 cells were counted at random.
Quantitative RT-PCR analysis
Purification of mouse liver microsomes
Microsomes were isolated from livers from wild type and transgenic ELOVL1 over-expressing mice (Kemp et al manuscript in preparation) by differential centrifugation as described by Baudhuin et al (Baudhuin et al 1964), with minor modifications. Livers were washed with ice-cold homogenization buffer containing 250 mM sucrose, 2 mM EDTA, 2 mM DTT and 5 mM MOPS (pH 7.4), minced and homogenized using a potter tissue grinder with Teflon pestle with 5 strokes at 500 rpm. A post-nuclear supernatant was produced by centrifugation at 600 g for 10 min. The supernatant was centrifuged at 22,500 g for 10 min and the pellet was discarded. Next, the supernatant was centrifuged for 1 h at 100,000 g to obtain a microsomal fraction. The pellet was resuspended in homogenization buffer containing 10 mg/mL methyl-β-cyclodextrin and sonicated for 4 times 5 seconds at 8 W with a 1 minute interval. The microsomal membranes were collected by centrifugation at 100,000 g for 1 h. Finally, the microsomes were resuspended in homogenization buffer and stored at -80°C until further use. All steps were carried out at 4°C. Protein concentrations were determined using BCA as described (Smith et al 1985).
Fatty acid elongation assay
The fatty acid elongation assay was carried out using a method adapted from Nagi et al (Nagi et al 1989). The reaction mixture contained 50 mM potassium phosphate buffer (pH 6.5), 10 mg/mL α-cyclodextrin, 1 mM NADPH, 5 μM rotenone, 60 μM [2-14 C] malonyl-CoA (6.5 dpm/pmol) (American Radiolabeled Chemicals, St Louis, MO) and 20 μM C16:0-CoA or 20 μM C22:0-CoA (Avanti Polar Lipids, Alabaster, AL), in a total volume of 200 μL. The reaction was started by adding 100 μg protein of the microsomal fraction and allowed to proceed for 30 min at 37°C. NADPH dependency was tested by performing the reaction without NADPH. Reactions were carried out with or without BF or BF-CoA (100 – 400 μM). The reaction was stopped by adding 200 μL 5 M KOH in 10% methanol, saponified at 65°C for 1 h and acidified by adding 200 μL 5 N HCl and 200 μL 96% ethanol. Fatty acids were extracted three times with 1 mL hexane and the hexane phases were collected in a scintillation vial to which 10 mL scintillation cocktail (Ultima-Gold, Perkin Elmer) was added and radioactivity counted.
Synthesis of bezafibroyl-CoA (BF-CoA)
BF-CoA was synthesized by a method adapted from Rasmussen et al (Rasmussen et al 1990). Dichloromethane (DCM) and tetrahydrofuran (THF) (Merck) were dried with molecular sieve deperox (Fluka). Triethylamine and ethylchloroformate (Merck) were diluted to 1 M with dry DCM. The reaction contained 36 μmol BF dissolved in 1.4 mL DCM/THF (5:2) and 40 μL 1 M triethylamine. The reaction mixture was incubated at room temperature for 10 min under constant stirring and under an atmosphere of nitrogen. After 10 min, 40 μL 1 M ethylchloroformate was added and the incubation was continued for 45 min. After the incubation, the mixture was dried under nitrogen and dissolved in 0.5 mL tert-butanol. Next, 40 μmol CoA trilithium salt (Sigma-Aldrich) dissolved in 0.5 mL 0.4 M potassium bicarbonate was added and the sample was incubated for 30 min at room temperature. The reaction was stopped by adding 100 μL 0.1 N HCl. BF-CoA was purified using a C18 solid phase extraction column (JTBaker). The column was eluted by a gradient of acetonitrile and 40 mM ammonium acetate, starting with 10% acetonitrile and 90% 40 mM ammonium acetate increasing to 50% acetonitrile and 50% 40 mM ammonium acetate. Acetonitrile was evaporated and purity was checked by HPLC. BF-CoA was quantified using 5,5’-dithiobis-(2-nitrobenzoic) acid (DTNB) (Sigma-Aldrich). The method used was an adaptation of that of Ellman (Ellman 1959). BF-CoA was diluted in 20 μM MES buffer pH 6.0, an equal volume of 2 M NaOH was added and the sample was incubated for 30 min at 50°C. The reaction was neutralized with 2 M HCl. Absorbance at 412 nm was measured and the concentration was determined using a calibration curve of CoA trilithium salt (Sigma-Aldrich).
Effect of BF on endogenous VLCFA levels and de novo C26:0 synthesis in fibroblasts from patients with X-ALD
The effect of BF on C26:0 levels is independent of induction of mitochondrial or peroxisomal β-oxidation
BF directly inhibits fatty acid elongation
Synthetic PPAR alpha ligands, like fibrates, are potentially interesting compounds to investigate as therapeutic agents in X-ALD because they are known to activate mitochondrial and peroxisomal fatty acid β-oxidation (Vazquez et al 2001). They might therefore reduce VLCFA accumulation by increasing VLCFA degradation. Indeed, Brown and colleagues demonstrated that treatment of two CCALD patients with clofibrate resulted in a reduction in VLCFA (Brown et al 1982). However, this reduction was not sustained. More recent experiments showed that fenofibrate induced expression of both ALDRP (ABCD2) and PMP70 (ABCD3) in the liver of Abcd1-deficient mice, but not in brain (Berger et al 1999). In Mdr1 -/- knockout mice induction of ALDRP and PMP70 in brain did occur, suggesting that fenofibrate is indeed cleared from the brain by Mdr1 (Berger et al 1999). These studies, however, did not report the effect on VLCFA levels in tissues. In this paper, we studied the effect of several classical fibrates and other synthetic PPAR ligands in a cell model for X-ALD, and show that BF but not the other fibrates reduced endogenous C26:0 levels. This C26:0 reducing effect could not be mimicked by other PPAR-ligands which means that the effect is PPAR independent. BF has been demonstrated to induce mitochondrial β-oxidation (Bonnefont et al 2009; Djouadi et al 2005). Blocking the induction of mitochondrial β-oxidation with MK-886 did not prevent the reduction of D3-C26:0 de novo synthesis in X-ALD fibroblast by BF. We also showed that the peroxisomal C26:0 β-oxidation capacity in X-ALD skin fibroblasts increased with 35% upon treatment with BF. However this does not seem to be the only mechanism of reduction of VLCFA in fibroblasts incubated with BF, because in cells from patients with a peroxisome biogenesis disorder in which peroxisomal β-oxidation is completely deficient, BF lowered D3-C26:0 levels as well. This strongly suggested that BF might reduce C26:0 levels primarily by inhibiting C26:0 synthesis. To test this we measured de novo synthesis of D3-C26:0 from D3-C16:0 in X-ALD fibroblasts. BF indeed decreased de novo synthesis of D3-C26:0 in a concentration-dependent manner. At a concentration of 400 μM BF, D3-C26:0 levels in X-ALD fibroblasts were at the level of control fibroblasts. The rate limiting enzymes involved in synthesis of C26:0 from C16:0 are ELOVL6 (elongation of C16:0 to C22:0) and ELOVL1 (elongation of C22:0 to C26:0) (Kemp and Wanders 2010; Ofman et al 2010). By qPCR we showed that expression levels of these enzymes are not affected in fibroblasts incubated with BF suggesting a direct inhibition of VLCFA synthesis. Previously using rat liver microsomes other investigators showed that BF inhibits palmitoyl-CoA (C16:0-CoA) elongation in an in vitro assay (Sanchez et al 1993; Vazquez et al 1995). We used purified microsomes from wild type and ELOVL1 over-expressing mice to test the effect of BF on elongation of both long-chain fatty acids (LCFA) and VLCFA. Our results demonstrate that BF-CoA, but not free BF, is a potent inhibitor of both LCFA and VLCFA elongation. It should be noted, however, that these results do not allow us to demonstrate at which level BF inhibits VLCFA synthesis. Fatty acid elongation requires four sequential reaction steps: (i) condensation between the fatty acyl-CoA and malonyl-CoA to form 3-ketoacyl-CoA; (ii) reduction using NADPH to form 3-hydroxyacyl-CoA; (iii) dehydration to trans-2-enoyl-CoA; and (iv) reduction to fully elongated fatty acyl-CoA. The initial condensation reaction is catalyzed by the enzyme referred to as “elongation of very long-chain fatty acids” (ELOVL) and is considered to be rate limiting (Cinti et al 1992). While seven elongases have been identified in mammals (designated ELOVL1-ELOVL7)(Jakobsson et al 2006), only a single enzyme has been identified yet for the subsequent reaction step (Jakobsson et al 2006). Identification of the specific enzyme(s) affected by BF is not a trivial thing and requires detailed analysis of all enzymes involved, including: 3-ketoacyl-CoA reductase (HSD17B12), 3-hydroxyacyl dehydratase (HACD3) and the trans-2,3-enoyl-CoA reductase (TECR). This will be the subject of future studies.
The work described in the paper shows that inhibition of VLCFA synthesis by pharmacological means could be a feasible treatment option for X-ALD. BF is a good candidate for this approach. BF lowers the levels of C26:0 by a direct inhibition of the synthesis. Mouse studies to evaluate the in vivo effect of BF treatment on VLCFA in X-ALD mice would be interesting; however, the effect of fibrates is quite different in rodents and humans. Watanabe et al demonstrated that rats and mice are unusable as a model system (for primates) to the study the effect of BF (Watanabe et al 1989). BF has a proven safety profile for (long-term) use in humans. With a daily dose of 200 mg of BF peak plasma levels of 50 μM can be reached, with a maximum daily dose of 800 mg of BF therapeutic levels might be reached in plasma (Miller and Spence 1998). A small scale proof of principle clinical trial is currently ongoing to evaluate the effect in X-ALD patients.
We thank Femke Stet, Petra Mooyer, and Henk van Lenthe for expert technical assistance. This research was supported by the Netherlands Organization for Scientific Research (VIDI-grant number 91786328), the European Union Framework Programme 7 (grant number LeukoTreat 241622). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Conflict of interest
This research was supported by the Netherlands Organization for Scientific Research (VIDI-grant number 91786328), the European Union Framework Programme 7 (grant number LeukoTreat 241622). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.